Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19361562 | 0.85 | ALDH1A1 (0.38) | ACACBALDH1A1MAPTRXFP1 | |
| SCHEMBL30130072 | 0.85 | ALDH1A1 (0.31) | ALDH1A1MAPTRXFP1 | |
| SCHEMBL16920270 | 0.84 | ALDH1A1 (0.30) | ALDH1A1MAPTRXFP1 | |
| SCHEMBL14945334 | 0.80 | ALDH1A1 (0.30) | ALDH1A1MAPTRXFP1 | |
| SCHEMBL18914280 | 0.80 | ACACB (0.33) | ACACBALDH1A1MAPTRXFP1 | |
| SCHEMBL28807134 | 0.80 | ACACA (0.36) | ACACBALDH1A1MAPTRXFP1 | |
| SCHEMBL29072078 | 0.79 | ALDH1A1 (0.34) | ALDH1A1MAPTRXFP1 | |
| SCHEMBL19369287 | 0.79 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL14945530 | 0.78 | GRIN2D (0.35) | ALDH1A1MAPTRXFP1 | |
| SCHEMBL14945486 | 0.77 | MAPT (0.44) | ACACBALDH1A1MAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4364795-A2 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | Gilead Apollo, LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11912718-B2 | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | GILEAD APOLLO, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912718-B2 | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | GILEAD APOLLO, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912718-B2 | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | GILEAD APOLLO, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| EP-3423456-B1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | GILEAD APOLLO LLC (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-4010344-A1 | THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-06-15 | — | — | EP | disclosed |
| US-11352371-B2 | Thienopyrimidine derivatives as ACC inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220064181-A1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | GILEAD APOLLO, LLC | 2022-03-03 | — | — | US | disclosed |
| US-20210053990-A1 | THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| WO-2021030142-A1 | THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20170267690-A1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | J.P. LAWSON CONSULTING LLC | 2017-09-21 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2013071169-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267690-A1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | ACACA, ACACB, COASY | ACACB 2/4885ALDH1A1 164/4885MAPT 1648/4885 |
| US-11912718-B2 | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | ACACA, ACACB, COASY | ACACB 2/4885ALDH1A1 164/4885MAPT 1648/4885 |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ACACB 2/4885ALDH1A1 104/4885MAPT 2490/4885 |
| US-11352371-B2 | Thienopyrimidine derivatives as ACC inhibitors and uses thereof | ACACB, ACACA, ACAT2 | ACACB 1/4885ALDH1A1 103/4885MAPT 2124/4885 |
| US-20220064181-A1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | ACACA, ACACB, COASY | ACACB 2/4885ALDH1A1 164/4885MAPT 1648/4885 |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ACACB 2/4885ALDH1A1 104/4885MAPT 2490/4885 |
| US-20210053990-A1 | THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ACACB 2/4885ALDH1A1 121/4885MAPT 2026/4885 |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ACACB 2/4885ALDH1A1 104/4885MAPT 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.